| abstract |
Use of a PDE4 inhibitor selected from the group consisting of the following compounds Nos. (1), (2), (9), (11), (21), (27), (44), (52), (53), (56) and (57) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the regenerative treatment of osteoarthritis, chondrodystrophy, degenerative discopathy and / or meniscus injury: ** Formula ** |